Original Article
Increased Need for Thyroxine in Women with Hypothyroidism during Estrogen Therapy
N Engl J Med 2001; 344:1743-1749June 7, 2001
- Abstract
Background
Women with hypothyroidism that is being treated with thyroxine often need higher doses when they are pregnant. Whether this need can be attributed solely to estrogen-induced increases in serum thyroxine-binding globulin or whether other factors are involved is not known.
Methods
In 11 postmenopausal women with normal thyroid function and 25 postmenopausal women with hypothyroidism treated with thyroxine, I assessed thyroid function before they started estrogen therapy and every 6 weeks for 48 weeks thereafter. The women with hypothyroidism included 18 women receiving thyroxine-replacement therapy and 7 women receiving thyrotropin-suppressive thyroxine therapy. On each occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measured.
Results
In the women with normal thyroid function, the serum free thyroxine and thyrotropin concentrations did not change, whereas at 12 weeks the mean (±SD) serum thyroxine concentration had increased from 8.0±0.9 μg per deciliter (103±12 nmol per liter) to 10.4±1.5 μg per deciliter (134±19 nmol per liter, P<0.001) and the serum thyroxine-binding globulin concentration had increased from 20.3±3.5 mg per liter to 31.3±3.2 mg per liter (P<0.001). The women with hypothyroidism had similar increases in serum thyroxine and thyroxine-binding globulin concentrations during estrogen therapy, but their serum free thyroxine concentration decreased from 1.7±0.4 ng per deciliter (22±5 pmol per liter) to 1.4±0.3 ng per deciliter (18±4 pmol per liter, P<0.001) and their serum thyrotropin concentration increased from 0.9±1.1 to 3.2±3.1 μU per milliliter (P<0.001). The serum thyrotropin concentrations increased to more than 7 μU per milliliter in 7 of the 18 women in the thyroxine-replacement group and to more than 1 μU per milliliter in 3 of the 7 women in the thyrotropin-suppression group.
Conclusions
In women with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for thyroxine.
Media in This Article
Figure 2
Mean (±SD) Serum Concentrations of Free Thyroxine (Panels A and C) and Thyrotropin (Panels B and D) in 11 Women with Normal Thyroid Function, 18 Women with Hypothyroidism in the Thyroxine-Replacement Group, and 7 Women with Hypothyroidism in the Thyrotropin-Suppression Group, All of Whom Received Estrogen Therapy for 48 Weeks.Figure 3
Serial Measurements of Serum Thyrotropin in 18 Women with Hypothyroidism in the Thyroxine-Replacement Group (Panel A) and 7 Women with Hypothyroidism in the Thyrotropin-Suppression Group (Panel B), All of Whom Received Estrogen Therapy for 48 Weeks.Article Activity
- Article
Women with hypothyroidism need an average of 45 percent more thyroxine during pregnancy to maintain euthyroidism.1-5 The possible causes of this increased need include an increase in serum thyroxine-binding globulin concentrations, degradation of thyroid hormone by the placenta, transfer of thyroxine from mother to fetus, and increased maternal clearance of thyroxine.1-6 Any of these factors would lead to a decrease in the serum free thyroxine concentration. In women with normal thyroid function,6 thyroxine secretion can increase to compensate for a decrease in the serum free thyroxine concentration, but it cannot increase in women with hypothyroidism.
Among the factors that may affect the need for thyroxine in pregnant women, only the increase in the serum thyroxine-binding globulin concentration is induced by estrogen. The administration of estrogen causes dose-dependent increases in the serum concentrations of thyroxine-binding globulin and thyroxine in women with normal thyroid function,6,7 but its effects in women with hypothyroidism are not known. I undertook this study to determine the effects of the administration of estrogen on pituitary–thyroid function in normal women and in women receiving thyroxine therapy for chronic hypothyroidism.
Methods
Study Subjects
Postmenopausal women who had indications for estrogen therapy and who agreed to take estrogen were asked to participate in the study. The indications for estrogen therapy included hot flashes, excessive sweating, and the treatment or prevention of osteoporosis. A total of 36 women were recruited: 11 women with normal thyroid function and no known medical problems and 25 women with primary hypothyroidism diagnosed between 18 and 68 months earlier (mean [±SD], 47±9 months) who had received the same doses of thyroxine for more than 9 months. Of these 25 women, 18 were receiving thyroxine-replacement therapy for hypothyroidism caused by chronic autoimmune thyroiditis (in 10 women), previous radioactive iodine therapy (in 4 women), or total thyroidectomy (in 4 women). The remaining seven women had previously undergone thyroidectomy and radioactive iodine treatment for thyroid cancer and were receiving thyrotropin-suppressive thyroxine therapy. These two groups are referred to here as the thyroxine-replacement group and the thyrotropin-suppression group, respectively. The study was approved by the institutional review board, and all the women gave written informed consent.
Study Protocol
Estrogen therapy was initiated after a clinical evaluation that included a physical examination and mammography. All the women received conjugated estrogens in a daily oral dose of 0.625 mg, and women who had not undergone hysterectomy also received medroxyprogesterone acetate in a dose of 5 mg per day for 12 days of each month. After 12 weeks of treatment, the dose of conjugated estrogens was decreased to 0.3 mg per day in one woman because of breast tenderness; the dose was increased to 1.25 mg daily in another woman because of persistent menopausal symptoms. For these two women, only the data obtained before the dose was changed were included in the analysis. The women had follow-up visits every 6 weeks for 48 weeks. At each visit, thyroid function was assessed clinically, and serum thyroxine, the thyroid hormone–binding index, free thyroxine, thyrotropin, and thyroxine-binding globulin were measured. Serum thyroglobulin was measured every 12 weeks in the women in the thyrotropin-suppression group. The clinical assessment included a focused history taking and a physical examination pertinent to thyroid dysfunction.
The women who were being treated with thyroxine continued to take the same brand and dose of thyroxine they had been taking before the study. The dose was increased in the women in the thyroxine-replacement group if the serum thyrotropin concentration increased to more than 7 μU per milliliter. The dose was increased in the women in the thyrotropin-suppression group if the serum thyrotropin concentration increased to more than 1 μU per milliliter. Data obtained after the dose of thyroxine was increased were not included in the analysis. At the end of the 48-week study period, all samples from each woman were reanalyzed with a single assay, and these results were used in the statistical analyses.
Laboratory Methods
Serum thyroxine and the thyroid hormone–binding index were measured with the use of kits from Abbott Laboratories (Abbott Park, Ill.). The serum free thyroxine index was calculated as the product of the serum thyroxine concentration and the thyroid hormone–binding index value. Serum free thyroxine was measured by a two-step radioimmunoassay with the use of kits from DiaSorin (Stillwater, Minn.). Serum thyrotropin was measured by fluoroimmunoassay with the use of kits from Wallac Oy (Turku, Finland). The lower limit of detectability with the assay was 0.002 μU per milliliter, and the normal range was 0.5 to 5.0 μU per milliliter. Serum thyroxine-binding globulin and thyroglobulin were measured by radioimmunoassay at Nichols Laboratories (San Juan Capistrano, Calif.). All other measurements (of thyroxine, thyrotropin, the thyroid hormone–binding index, and free thyroxine) were performed at the University Hospitals of Cleveland. The intraassay coefficients of variation of these assays varied from 1.2 percent to 3.5 percent.
Statistical Analysis
The pretreatment characteristics of the women with hypothyroidism and the women with normal thyroid function were compared by means of unpaired t-tests. Within each group and subgroup, the data obtained both before the administration of estrogen and after 12, 24, and 48 weeks of estrogen therapy were analyzed by repeated-measures analysis of variance and two-sided t-tests. The results for the women who received medroxyprogesterone were first analyzed separately from the results for those who did not. Because medroxyprogesterone had no effect on thyroid function, the results were then combined.
Results
The ages and weights of the women with hypothyroidism and the women with normal thyroid function were similar (Table 1Table 1
Base-Line Characteristics and Results of Thyroid-Function Tests in the Women with Normal Thyroid Function and the Women with Hypothyroidism.). The 7 women in the thyrotropin-suppression group were taking higher daily doses of thyroxine than the 18 women in the thyroxine-replacement group. At base line, all the women had high serum gonadotropin concentrations and low serum estradiol concentrations, findings consistent with their postmenopausal state (data not shown).All but five women completed the study. Serious medical illnesses requiring the discontinuation of estrogen developed in two of these women: pulmonary embolus in one woman with normal thyroid function, at six months, and breast cancer in one woman with hypothyroidism, at nine months. Three additional women elected to discontinue estrogen therapy after six to nine months for personal reasons. The data for these five women up to the time they discontinued estrogen therapy were included in the analysis.
Thyroid Function at Base Line
As compared with the women with normal thyroid function, the women in the thyroxine-replacement group had similar serum concentrations of thyrotropin and thyroxine but higher serum free thyroxine index values and serum free thyroxine concentrations (Table 1). The women in the thyrotropin-suppression group had lower serum thyrotropin concentrations and higher serum thyroxine concentrations, serum free thyroxine concentrations, and serum free thyroxine index values than the women with normal thyroid function (Table 1). The differences reflected the higher doses of thyroxine given to the women in the thyrotropin-suppression group. The serum thyroxine-binding globulin concentrations were similar in all three groups.
Thyroid Function during Estrogen Therapy in the Women with Normal Thyroid Function
In the women with normal thyroid function, estrogen therapy for 6 weeks resulted in a significant increase in the mean (±SD) serum concentrations of thyroxine and thyroxine-binding globulin, and the values were slightly higher at 12 weeks (serum thyroxine, 10.4±1.5 μg per deciliter [134±19 nmol per liter]; serum thyroxine-binding globulin 31.3±3.2 mg per liter; P<0.001 for both comparisons with the base-line values), after which the values did not change materially (Figure 1Figure 1
Mean (±SD) Serum Concentrations of Thyroxine (Panels A and C) and Thyroxine-Binding Globulin (Panels B and D) in 11 Women with Normal Thyroid Function, 18 Women with Hypothyroidism in the Thyroxine-Replacement Group, and 7 Women with Hypothyroidism in the Thyrotropin-Suppression Group, All of Whom Received Estrogen Therapy for 48 Weeks.). The mean maximal increase in the serum thyroxine concentration was 2.4±1.0 μg per deciliter (31±13 nmol per liter). The increase in the serum thyroxine-binding globulin concentration was accompanied by a decrease in the thyroid hormone–binding index value (to a mean of 0.7±0.1 at 12 weeks, P<0.001). The serum free thyroxine index values did not change significantly (data not shown), nor did the serum free thyroxine or thyrotropin concentrations (Figure 2Figure 2Mean (±SD) Serum Concentrations of Free Thyroxine (Panels A and C) and Thyrotropin (Panels B and D) in 11 Women with Normal Thyroid Function, 18 Women with Hypothyroidism in the Thyroxine-Replacement Group, and 7 Women with Hypothyroidism in the Thyrotropin-Suppression Group, All of Whom Received Estrogen Therapy for 48 Weeks.).Thyroid Function during Estrogen Therapy in the Women with Hypothyroidism
The serum thyroxine-binding globulin concentrations increased at six weeks in response to estrogen therapy in the women with hypothyroidism that was being treated with thyroxine. The values reached a peak at 12 weeks (30.8±4.0 mg per liter, P<0.001) (Figure 1), after which they did not change substantially. The serum thyroxine concentrations increased in a parallel manner in these women. The 12-week values were 10.9±2.3 μg per deciliter (140±30 nmol per liter) for women in the thyroxine-replacement group and 14.5± 1.2 μg per deciliter (187±15 nmol per liter) for women in the thyrotropin-suppression group (P<0.001 for the comparisons with base-line values in both groups). The mean maximal increase in the serum thyroxine concentration was 2.5±1.0 μg per deciliter (32±13 nmol per liter) among the women in the thyroxine-replacement group and 3.3±0.8 μg per deciliter (42±10 nmol per liter) among the women in the thyrotropin-suppression group (P=1.00 and P=0.04, respectively, for the comparisons with the women with normal thyroid function). The thyroid hormone–binding index value in the women with hypothyroidism decreased to 0.8±0.1 (P<0.01 for the comparison with base line). The serum free thyroxine index values did not change in response to estrogen therapy.
In contrast to the stable level in the women with normal thyroid function, the serum free thyroxine concentration had decreased at 12 weeks in the women with hypothyroidism from 1.7±0.4 ng per deciliter (22±5 pmol per liter) to 1.4±0.3 ng per deciliter (18±4 pmol per liter, P<0.001). These concentrations had decreased at 12 weeks from 1.5±0.3 ng per deciliter (19±4 pmol per liter) to 1.2±0.3 ng per deciliter (15±4 pmol per liter, P=0.01) in the women in the thyroxine-replacement group and from 2.1±0.3 ng per deciliter (27±4 pmol per liter) to 1.7±0.2 ng per deciliter (22±3 pmol per liter, P=0.01) in the women in the thyrotropin-suppression group. The serum free thyroxine concentration remained lower than the base-line concentration throughout the study (Figure 2). This decrease was accompanied by a significant increase in the serum thyrotropin concentration in both subgroups (P=0.03 and P=0.05, respectively) at 12 weeks (Figure 2 and Figure 3Figure 3
Serial Measurements of Serum Thyrotropin in 18 Women with Hypothyroidism in the Thyroxine-Replacement Group (Panel A) and 7 Women with Hypothyroidism in the Thyrotropin-Suppression Group (Panel B), All of Whom Received Estrogen Therapy for 48 Weeks.). The decrease in the serum free thyroxine concentration correlated inversely with the increase in the serum thyrotropin concentration in the women in the thyroxine-replacement group (r=0.68, P<0.001) and that in the thyrotropin-suppression group (r=0.66, P=0.04).The changes in the serum thyrotropin concentrations shown in Figure 3 were clinically important in 10 of the 25 women with hypothyroidism. Specifically, seven women in the thyroxine-replacement group had increases in the serum thyrotropin concentration to more than 7 μU per milliliter, and their dose of thyroxine was therefore increased. Only one of these seven women had any symptoms or signs of hypothyroidism. None of the women whose serum thyrotropin concentrations remained lower than 7 μU per milliliter had symptoms of hypothyroidism. The serum thyrotropin concentrations increased to more than 1 μU per milliliter in three women in the thyrotropin-suppression group; none had clinical manifestations of hypothyroidism. However, two of these three women also had increases in the serum thyroglobulin concentration from undetectable values (less than 0.5 ng per milliliter) to 2.5 ng per milliliter and 6 ng per milliliter, respectively. The doses of thyroxine in these three women had to be increased by 25 to 50 μg per day to achieve thyrotropin suppression similar to pretreatment values.
Discussion
This study demonstrates that women with hypothyroidism that is being treated with thyroxine who then receive estrogen have alterations in serum free thyroxine and thyrotropin concentrations that are small but potentially clinically important. In contrast, the serum concentrations of free thyroxine and thyrotropin did not change in the women with normal thyroid function. The increase in the serum thyrotropin concentrations in the women in the thyroxine-replacement group might have resulted in symptoms of hypothyroidism had their doses not been increased. Similarly, an increase in the serum thyrotropin concentration could potentially be harmful in women receiving thyrotropin-suppressive thyroxine therapy for thyroid cancer.
The uniformity of the changes in the serum concentrations of free thyroxine and thyrotropin indicates that noncompliance with thyroxine therapy is an unlikely explanation for the reported alterations. Furthermore, because of the chronic nature of the deficiency of thyroid hormone in the women, it is unlikely that these alterations reflect a decrease in residual functioning thyroid tissue.
The alterations in the serum concentrations of free thyroxine and thyrotropin in the women with hypothyroidism most likely resulted from estrogen-induced increases in the serum thyroxine-binding globulin concentration. This increase in binding would be expected to slow the entry of thyroxine into cells, including pituitary cells, thereby reducing thyroid hormone action in tissue. Alternatively, estrogen might lower the serum free thyroxine concentration by increasing the clearance of thyroxine. However, that would be expected to lower the serum concentrations of both thyroxine and free thyroxine. In fact, in subjects with normal thyroid function, estrogen therapy is known to slow the fractional daily clearance of thyroxine but not to alter the total daily clearance.8 The reported clinical and biochemical improvement during the administration of estrogen in women with hyperthyroidism caused by Graves' disease and those with thyrotoxicosis facticia8,9 accords with the results of the current study.
Pregnant women with hypothyroidism who are treated with thyroxine require an average increase of 45 percent in the dose of thyroxine to maintain euthyroidism.1,3,5 In this study, only a minority of the women with hypothyroidism had increases in their serum thyrotropin concentrations that were sufficient to warrant an increase in the dose of thyroxine. However, the increases in the serum concentrations of thyroxine and thyroxine-binding globulin that occur during pregnancy7 in women with normal thyroid function are similar to those that occur during estrogen therapy. Thus, it is likely that hyperestrogenemia does not mediate all of the alterations that occur in pregnant women. It is unlikely that changes in another transport protein for thyroxine, transthyretin, contribute to the alterations, since the serum transthyretin concentration does not change during pregnancy.7
Estrogen raises the serum thyroxine-binding globulin concentration by increasing sialylation of the protein, which slows its clearance,10 and also by enhancing its biosynthesis.11 Conversely, androgens decrease the serum thyroxine-binding globulin concentration and therefore decrease the serum thyroxine concentration.12 In women with hypothyroidism treated with thyroxine who are given an androgen, the serum free thyroxine concentration sometimes increases sufficiently to cause clinical manifestations of hyperthyroidism.12
In summary, women with no thyroid disease adapt quickly to estrogen-induced increases in the serum thyroxine-binding globulin concentration. In contrast, women with hypothyroidism who are treated with estrogen have a decrease in the serum free thyroxine concentration sufficient to increase the serum thyrotropin concentration, resulting in an increased need for thyroxine. Thus, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated in women with hypothyroidism, especially in those with thyroid cancer who are being treated with thyroxine to achieve thyrotropin suppression.
Presented in part at the 81st Endocrine Society Meeting, San Diego, Calif., June 12–15, 1999.
Supported in part by a grant from Knoll Pharmaceutical.
I am indebted to the referring physicians and the nursing staff at the Clinical Research Center and the outpatient facility for their help in conducting the study; and to Dr. Faramarz Ismail-Beigi and Dr. Saul Genuth for reviewing the manuscript.
Source Information
From the Division of Clinical and Molecular Endocrinology, Case Western Reserve University and the University Hospitals of Cleveland, Cleveland.
Address reprint requests to Dr. Arafah at the Division of Clinical and Molecular Endocrinology, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106.
- References
References
1
Mandel SJ ,Larsen PR ,Seely EW ,Brent GA . Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990;323:91-96
Full Text | Web of Science | Medline2
Utiger RD . Therapy of hypothyroidism: when are changes needed? N Engl J Med 1990;323:126-127
Full Text | Web of Science | Medline3
Mandel SJ ,Brent GA ,Larsen PR . Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502
Web of Science | Medline4
Toft AD . Thyroxine therapy. N Engl J Med 1994;331:174-180[Erratum, N Engl J Med 1994;331:1035.]
Full Text | Web of Science | Medline5
Burrow GN ,Fisher DA ,Larsen PR . Maternal and fetal thyroid function. N Engl J Med 1994;331:1072-1078
Full Text | Web of Science | Medline6
Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams textbook of endocrinology. 9th ed. Philadelphia: W.B. Saunders, 1998:397-410.
7
Skjoldebrand L ,Brundin J ,Carlstrom A ,Pettersson T . Thyroid associated components in serum during normal pregnancy. Acta Endocrinol (Copenh) 1982;100:504-511
Medline8
Dowling JT ,Freinkel N ,Ingbar SH . The effect of estrogens upon the peripheral metabolism of thyroxine. J Clin Invest 1960;39:1119-1130
CrossRef | Web of Science | Medline9
Zaninovich AA . Effects of oestrogens on thyroxine turnover in hyperthyroidism. Acta Endocrinol (Copenh) 1972;71:491-497
Medline10
Ain KB ,Mori Y ,Refetoff S . Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987;65:689-696
CrossRef | Web of Science | Medline11
Robbins J ,Cheng SY ,Gershengorn MC ,Glinoer D ,Cahnmann HJ ,Edelnoch H . Thyroxine transport proteins of plasma: molecular properties and biosynthesis. Recent Prog Horm Res 1978;34:477-519
Medline12
Arafah BM . Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med 1994;121:247-251
Web of Science | Medline
- Citing Articles (55)
Citing Articles
1
Deepak Khandelwal, Nikhil Tandon. (2012) Overt and Subclinical Hypothyroidism. Drugs 72:1, 17-33
CrossRef2
Shilpi Rajoria, Robert Suriano, Andrea L. George, Arulkumaran Shanmugam, Casey Jussim, Edward J. Shin, Augustine L. Moscatello, Jan Geliebter, Angelo Carpi, Raj K. Tiwari. (2011) Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomedicine & Pharmacotherapy
CrossRef3
Madhuri Devdhar, Rebecca Drooger, Marieta Pehlivanova, Gurdeep Singh, Jacqueline Jonklaas. (2011) Levothyroxine Replacement Doses Are Affected by Gender and Weight, But Not Age. Thyroid 21:8, 821-827
CrossRef4
Fabrice Herin, Elisa Boutet-Robinet, Aude Levant, Sylvain Dulaurent, Mimoza Manika, Florence Galatry-Bouju, Philippe Caron, Jean-Marc Soulat. (2011) Thyroid Function Tests in Persons with Occupational Exposure to Fipronil. Thyroid 21:7, 701-706
CrossRef5
Hyunju Ryoo, Jiyoung Woo, Younyoung Kim, Chaeyoung Lee. (2011) Heterogeneity of genetic associations of CDKAL1 and HHEX with susceptibility of type 2 diabetes mellitus by gender. European Journal of Human Genetics 19:6, 672-675
CrossRef6
Samuel A. Pauli, Caleb B. Kallen. 2011. Endocrine Disorders and Infertility. , 90-101.
CrossRef7
Jaume Arroyo Bros, Pilar Gil Lluís, Gemma Llauradó Cabot, Assumpta Caixàs Pedragós. (2011) Hipotiroidismo primario: consideraciones para una buena utilización del tratamiento con levotiroxina. Medicina Clínica 136:5, 207-214
CrossRef8
Ana Paula Santin, Tania Weber Furlanetto. (2011) Role of Estrogen in Thyroid Function and Growth Regulation. Journal of Thyroid Research 2011, 1-7
CrossRef9
Antonio De Vivo, Alfredo Mancuso, Annamaria Giacobbe, Mariacarla Moleti, Laura Maggio Savasta, Rosanna De Dominici, Antonio Maria Priolo, Francesco Vermiglio. (2010) Thyroid Function in Women Found to Have Early Pregnancy Loss. Thyroid 20:6, 633-637
CrossRef10
Bronwyn G.A. Stuckey, Doreen Yeap, Simon R. Turner. (2010) Thyroxine replacement during super-ovulation for in vitro fertilization: a potential gap in management?. Fertility and Sterility 93:7, 2414.e1-2414.e3
CrossRef11
Jacqueline Jonklaas. (2010) Sex and Age Differences in Levothyroxine Dosage Requirement. Endocrine Practice 16:1, 71-79
CrossRef12
Chaya G. Bhuvaneswar, Ross J. Baldessarini, Veronica L. Harsh, Jonathan E. Alpert. (2009) Adverse Endocrine and Metabolic Effects of Psychotropic Drugs. CNS Drugs 23:12, 1003-1021
CrossRef13
Rundsarah Tahboub, Baha M. Arafah. (2009) Sex steroids and the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 769-780
CrossRef14
Geeta Chadha, Mamta Goel. (2009) Hypothyroidism in Pregnancy. Apollo Medicine 6:4, 322-326
CrossRef15
Offie P. Soldin, Bethany E. Goughenour, Sappho Z. Gilbert, Helain J. Landy, Steven J. Soldin. (2009) Thyroid Hormone Levels Associated with Active and Passive Cigarette Smoking. Thyroid 19:8, 817-823
CrossRef16
2009. Thyroid Gland Testing. , 1-58.
CrossRef17
Chi-Un Pae, Laura Mandelli, Changsu Han, Byung-Joo Ham, Prakash S. Masand, Ashwin A. Patkar, David C. Steffens, Diana De Ronchi, Alessandro Serretti. (2009) Thyroid hormones affect recovery from depression during antidepressant treatment. Psychiatry and Clinical Neurosciences 63:3, 305-313
CrossRef18
James A Simon. (2009) Postmenopausal estrogen therapy: which route to take?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 146-147
CrossRef19
Patricia de Gortari, Karen Mancera, Antonieta Cote-Vélez, María Isabel Amaya, Adrián Martínez, Lorraine Jaimes-Hoy, Patricia Joseph-Bravo. (2009) Involvement of CRH-R2 receptor in eating behavior and in the response of the HPT axis in rats subjected to dehydration-induced anorexia. Psychoneuroendocrinology 34:2, 259-272
CrossRef20
Christian De Geyter, Sabine Steimann, Beat Müller, Marius E. Kränzlin, Christian Meier. (2009) Pattern of Thyroid Function During Early Pregnancy in Women Diagnosed with Subclinical Hypothyroidism and Treated with
l -Thyroxine Is Similar to That in Euthyroid Controls. Thyroid 19:1, 53-59
CrossRef21
Masanobu Yamada, Masatomo Mori. (2008) Mechanisms related to the pathophysiology and management of central hypothyroidism. Nature Clinical Practice Endocrinology & Metabolism 4:12, 683-694
CrossRef22
Luiz Felipe Bittencourt de Araujo, Renata Grozovsky, Mônica de Campos Pinheiro, Jorge José de Carvalho, Mário Vaisman, Denise P. Carvalho. (2008) Raloxifene effects on thyroid gland morphology in ovariectomized rats. Fertility and Sterility 90:4, 1211-1214
CrossRef23
NANETTE SANTORO. (2008) Symptoms of Menopause: Hot Flushes. Clinical Obstetrics and Gynecology 51:3, 539-548
CrossRef24
Andrea Lania, Luca Persani, Paolo Beck-Peccoz. (2008) Central hypothyroidism. Pituitary 11:2, 181-186
CrossRef25
Graziano Ceresini, Bruna Milli, Simonetta Morganti, Marcello Maggio, Alberto Bacchi-Modena, Maria Paola Sgarabotto, Carla Chirico, Pietro Di Donato, Paolo Campanati, Roberto Valcavi, Gian Paolo Ceda, Lewis E. Braverman, Giorgio Valenti. (2008) Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause 15:2, 326-331
CrossRef26
Venetsana Kyriazopoulou, Marina Michalaki, Neoklis Georgopoulos, Apostolos G Vagenakis. (2008) Recommendations for thyroxin therapy during pregnancy. Expert Opinion on Pharmacotherapy 9:3, 421-427
CrossRef27
George Mastorakos, Eftychia I. Karoutsou, Maria Mizamtsidi, George Creatsas. (2007) The menace of endocrine disruptors on thyroid hormone physiology and their impact on intrauterine development. Endocrine 31:3, 219-237
CrossRef28
Christoph J. Auernhammer, George Vlotides. (2007) Anterior pituitary hormone replacement therapy—a clinical review. Pituitary 10:1, 1-15
CrossRef29
Mark A. Ferrante. 2007. Endogenous Metabolic Disorders. , 827-864.
CrossRef30
Jayne A Franklyn. (2006) Does impaired secretion of gastric acid reduce absorption of levothyroxine?. Nature Clinical Practice Endocrinology & Metabolism 2:10, 542-543
CrossRef31
Centanni, Marco, Gargano, Lucilla, Canettieri, Gianluca, Viceconti, Nicola, Franchi, Antonella, Fave, Gianfranco Delle, Annibale, Bruno, . (2006) Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis. New England Journal of Medicine 354:17, 1787-1795
Full Text32
Claudia Panzer, Sarah Wise, Gemma Fantini, Dongwoo Kang, Ricardo Munarriz, Andre Guay, Irwin Goldstein. (2006) Impact of Oral Contraceptives on Sex Hormone-Binding Globulin and Androgen Levels: A Retrospective Study in Women with Sexual Dysfunction. The Journal of Sexual Medicine 3:1, 104-113
CrossRef33
M. O. Aken, S. W. J. Lamberts. (2005) Diagnosis and Treatment of Hypopituitarism: An Update. Pituitary 8:3-4, 183-191
CrossRef34
Bernadette Biondi, Sebastiano Filetti, Martin Schlumberger. (2005) Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice Endocrinology & Metabolism 1:1, 32-40
CrossRef35
J. Neulen. (2005) Störungen der Schilddrüsenfunktion. Der Gynäkologe 38:4, 315-318
CrossRef36
Hasnain M. Khandwala, Rajni Chibbar, Lawrence J. Worobetz. (2005) A Case of Celiac Disease Presenting With Malabsorption of l-Thyroxine. The Endocrinologist 15:1, 14-17
CrossRef37
&NA;. (2004) Body Mass Index and Insulin Resistance. Obstetrics & Gynecology 104:Supplement, 5S-10S
CrossRef38
Alexander, Erik K., Marqusee, Ellen, Lawrence, Jennifer, Jarolim, Petr, Fischer, George A., Larsen, P. Reed, . (2004) Timing and Magnitude of Increases in Levothyroxine Requirements during Pregnancy in Women with Hypothyroidism. New England Journal of Medicine 351:3, 241-249
Full Text39
Jeffrey M. Zigman. (2004) Authors' Response. Thyroid 14:6, 480-481
CrossRef40
Norman A. Mazer. (2004) Interaction of Estrogen Therapy and Thyroid Hormone Replacement in Postmenopausal Women. Thyroid 14:supplement 1, 27-34
CrossRef41
Michael T. McDermott. (2004) Thyroid Disease and Reproductive Health. Thyroid 14:supplement 1, 1-3
CrossRef42
Graziano Ceresini, Simonetta Morganti, Isabella Rebecchi, Luca Bertone, Gian Paolo Ceda, Alberto Bacchi-Modena, Mariapaola Sgarabotto, Monica Baldini, Fabrizio Ablondi, Giorgio Valenti, Lewis E. Braverman. (2004) A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 11:2, 176-179
CrossRef43
Caroline GP Roberts, Paul W Ladenson. (2004) Hypothyroidism. The Lancet 363:9411, 793-803
CrossRef44
Nagi Kumar, Kathryn A. Allen, Diane Riccardi, Barry B. Bercu, Alan Cantor, Sue Minton, Lodovico Balducci, Paul B. Jacobsen. (2004) Fatigue, Weight Gain, Lethargy and Amenorrhea in Breast Cancer Patients on Chemotherapy: Is Subclinical Hypothyroidism the Culprit?. Breast Cancer Research and Treatment 83:2, 149-159
CrossRef45
Nick Clarke, Udaya M Kabadi. (2004) Optimizing Treatment of Hypothyroidism. Treatments in Endocrinology 3:4, 217-221
CrossRef46
Jeffrey M. Zigman, Shmuel E. Cohen, Jeffrey R. Garber. (2003) Impact of Thyroxine-Binding Globulin on Thyroid Hormone Economy During Pregnancy. Thyroid 13:12, 1169-1175
CrossRef47
Marian Pavuk, Arnold J Schecter, Fatema Z Akhtar, Joel E Michalek. (2003) Serum 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Levels and Thyroid Function in Air Force Veterans of the Vietnam War. Annals of Epidemiology 13:5, 335-343
CrossRef48
(2003) References. Thyroid 13:1, 104-126
CrossRef49
Mark P. J. Vanderpump, W. Michael G. Tunbridge. (2002) Epidemiology and Prevention of Clinical and Subclinical Hypothyroidism. Thyroid 12:10, 839-847
CrossRef50
G Samsioe. (2002) The role of ERT/HRT. Best Practice & Research Clinical Obstetrics & Gynaecology 16:3, 371-381
CrossRef51
Marcy A. Adlersberg, Gerard N. Burrow. (2002) Focus on Primary Care Thyroid Function and Dysfunction in Women. Obstetrical & Gynecological Survey 57:Supplement, S1-S7
CrossRef52
Vahab Fatourechi. (2002) Subclinical Hypothyroidism. Treatments in Endocrinology 1:4, 211-216
CrossRef53
Utiger, Robert D., . (2001) Estrogen, Thyroxine Binding in Serum, and Thyroxine Therapy. New England Journal of Medicine 344:23, 1784-1785
Full Text54
&NA;. (2001) Estrogen increases thyroxine requirements in hypothyroidism. Reactions Weekly &NA;:856, 5
CrossRef55
&NA;. (2001) Estrogen increases thyroxine requirements in hypothyroidism. Inpharma Weekly &NA;:1292, 20
CrossRef
